DOCSLIB.ORG

Wo 2009/120182 A2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 October 2009 (01.10.2009) WO 2009/120182 A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 47/34 (2006.01) CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/US2008/013816 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, 18 December 2008 (18.12.2008) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (25) Filing Language: English UG, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/015,365 20 December 2007 (20.12.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 12/262,986 31 October 2008 (3 1.10.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant: EASTMAN CHEMICAL COMPANY [US/ ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, US]; 200 South Wilcox Drive, Kingsport, TN 37660 MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (US). (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (72) Inventor: WEMPE, Michael, Fitzpatrick; 4016 Rick Slaughter Court, Kingsport, TN 37660 (US). Published: (74) Agent: NELSON, Brett, L.; P.O. Box 5 11, Kingsport, — without international search report and to be republished TN 37662-5075 (US). upon receipt of that report (Rule 48.2(g)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR AC TIVES Figure 1 AQ38S (Left) and AQ38P (Right) Comparison (57) Abstract: Sulfo-polyester powders and sulfo-polyester blend powders, the incorporation of carriers and/or actives, and meth ods of making the powders as well as dispersions employing these powders. SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ACTIVES BACKGROUND OF THE INVENTION: Sulfo-polyesters (such as Eastman AQ polymers) are high molecular weight amorphous polyesters commonly dispersed directly in water without the need to incorporate organic co-solvents, surfactants, or amines. Sulfo-polyesters differ chiefly by their chemical makeup (i.e. they are composed of 5-sodiosulfoisophthalic acid (5- SSIPA) and various combinations of other materials, for example: terephthalic acid (TPA), isophthalic acid (IPA), ethylene glycol (EG), diethylene glycol (DEG), 1,4- cyclohexanedimethanol (CHDM), and/or 1,4-cyclohexanedicarboxylic acid (1,4- CHDA). The temperature where a glassy polymer becomes rubbery on heating, and vice versa upon cooling, is known as the 'glass transition temperature (Tg). Hence, the various sulfo-polyester polymers have different average Tg values. Sulfopolyesters are solid to semi-solid polymers and require warm to hot water with sufficient mixing time to prepare concentrated dispersions. Moreover, different sulfo-polyester polymer dispersions may possess trace volatile components and potentially cause odor. Therefore methods that improve dissolution and/or lower volatile content may be advantageous. BRIEF SUMMARY OF THE INVENTION: The present invention addresses solutions to issues previously described and enables the preparation of sulfopolyester polymer powders and/or blends containing carriers (e.g. surfactants) and/or actives, and dispersions of sulfopolyester or sulfopolyester blends with and without carriers and/or actives, having reduced odor, using water and/or solvent mixtures with sufficient mixing. An embodiment of the present invention concerns a composition comprising at least one sulfonated copolyester and at least one active agent, wherein said composition is a powder. Yet another embodiment concerns a method of increasing the bioavailability of an active agent comprising administering the composition described in the previous paragraph to a subject (i.e. an organism). Another embodiment concerns a method for producing a sulfonated copolyester powder containing an active agent comprising: a) dispersing at least one sulfonated coployester and at least one active agent in a solvent, or solvent mixture, to form a dispersion; and b) drying said dispersion to form a powder. Another embodiment concerns a method for producing a sulfonated copolyester powder containing an active agent comprising: a) dispersing at least one sulfonated copolyester in a solvent to form a dispersion; and b) drying said dispersion to form a powder; and c) mixing (grinding, milling, and the like) said sulfonated copolyester powder with at least one active agent. Yet another embodiment concerns a cosmetic composition, comprising the compositions described above and a cosmetically acceptable carrier. Another embodiment concerns a pharmaceutical or agricultural composition, comprising the compositions described above and a pharmaceutically or agriculturally acceptable carrier. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a side-by-side comparison of a sulfopolyester polymer and the corresponding powder. Figure 2 shows the chemical structures for various compound examples incorporated with sulfopolyester polymer powders. Figure 3A shows the oral dose blood concentration-time data for itraconazole for two dosing groups; and Figure 3B shows the oral dose blood concentration-time data for hydroxy- itraconazole for two dosing groups. DETAILED DESCRIPTION: The present invention concerns sulfo-polyester powders and sulfo-polyester blend powders, the incorporation of carriers and/or actives, and methods of making the powders as well as dispersions employing these powders. Sulfo-polyester powder(s) and sulfo-polyester powder blend(s) with and without carriers and/or actives are prepared by dispersing said sulfo-polyester powder(s) and sulfo-polyester powder blend(s) in a solvent or solvent mixture (e.g.. water, water and alcohol mixtures, etc) at various temperatures. The exact solvent, or solvent mixture, and temperatures used will be a function of the application end usage and/or required dispersion percentage. End uses of said sulfo-polyester powder(s) and sulfo-polyester powder blend(s) include sun care /skin care applications (i.e. creams, lotions and sprays), perfume applications (i.e. flavors, fragrances, essential oils, etc), hairstyling applications (i.e. hair gel and hairspray), color makeup and hairstyling applications, drug-delivery applications, and adhesive removal such as re-pulping of paper and plastic and glass recycling. As used throughout this application, the term "powder" shall mean particles in the range of 0.5 - 5000 µM. The science and technology of small particles is known as "micrometrics" (for a general review, see 'Physical Pharmacy and Pharmaceutical Sciences' Fifth Edition by Patrick J. Sinko, Lippincott Willams & Wilkins, 2006, ISBN: 0-7817-5027-X). The unit commonly used to describe particle size is the micrometer (µm). In general, optical microscopy may be used to measure particle- sizes of about 0.2 to about 100 µm; however, other techniques may also be used to determine approximate size ranges, such as sedimentation, coulter counter, airpermeability, sieving, etc. Techniques such as sieving, according to methods of the U.S. Pharmacopeia, may be used to determine 'powder fineness1, or other properties of the corresponding powders and/or powder blends; for example, particle size and size distribution (i.e. average particle size, particle-size distribution (frequency distribution curve), number and weight distributions, particle number), particle volume, particle shape and surface area, pore size, porosity, particle density, bulkiness, flow properties, etc. Because many powders have a tendency to contain a non-symmetric particle size distribution, it is common to plot the log-normal distribution; commonly, this method results in a linear relationship. Subsequently, the "geometric mean diameter" (dg; the particle size equivalent to 50% on the probability scale) may be obtained from plotting the logarithm of the particle size against the cumulative percent frequency on a probability scale. Therefore, as used throughout this application, powders shall be classified into different particle size ranges, such as: 'extremely fine powders' (i.e. dusty powders; 0.5-50 µm), 'fine powders' (50-100 µm), 'coarse powders' (100-1000 µm), and 'granular powders' (1000-5000 µm). In an embodiment of the present invention, the compositions are generally prepared by techniques such as lyophilization, spray-drying, jet milling, spray freeze- drying, fluidized-bed spray coating, supercritical fluid methods, etc. The different techniques are based on different mechanisms of droplet/particle formation and/or drying (for a general review, see 'Lyophilization of Biopharmaceuticals' edited by Henry R. Costantino and Michael J. Pikal, AAPS Press, 2004, ISBN: 0-971 1767-6-0). The compositions are prepared by dispersing a sulfo-polyester or sulfo- polyester blend in a solvent, or solvent mixture (e.g. water, water and alcohol mixtures, etc), and optionally at least one active at various temperatures to form a dispersion. The dispersion can also include a carrier. The starting sulfo-polyester or sulfo-polyester blend can be in pellet form, or, for example, can be a sample that has been chipped or ground up. The exact solvent, or solvent mixture, and temperatures used will be a function of the application end usage and/or required dispersion percentage. Typical starting dispersions contain about 35% to about 2% by weight sulfo- polyester or sulfo-polyester blend, or between about 25% to about 5% weight sulfo- polyester or sulfo-polyester blend, or between about 15% to about 7% by weight sulfo-polyester or sulfo-polyester blend.
Recommended publications
  • Phthalates: Toxicology and Food Safety – a Review

    Phthalates: Toxicology and Food Safety – a Review

    Czech J. Food Sci. Vol. 23, No. 6: 217–223 Phthalates: Toxicology and Food Safety – a Review PŘEMYSL MIKULA1, ZDEŇKA SVOBODOVÁ1 and MIRIAM SMUTNÁ2 1Department of Veterinary Public Health and Toxicology and 2Department of Biochemistry and Biophysics, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic Abstract MIKULA P., SVOBODOVÁ Z., SMUTNÁ M. (2005): Phthalates: toxicology and food safety – a review. Czech J. Food Sci., 23: 217–223. Phthalates are organic substances used mainly as plasticisers in the manufacture of plastics. They are ubiquitous in the environment. Although tests in rodents have demonstrated numerous negative effects of phthalates, it is still unclear whether the exposure to phthalates may also damage human health. This paper describes phthalate toxicity and toxicokinetics, explains the mechanisms of phthalate action, and outlines the issues relating to the presence of phthalates in foods. Keywords: di(2-ethylhexyl)phthalate; dibutyl phthalate; peroxisome proliferators; reproductive toxicity Phthalic acid esters, often also called phtha- air, soil, food, etc.). People as well as animals lates, are organic substances frequently used can be exposed to these compounds through in many industries. They are usually colourless ingestion, inhalation or dermal exposure, and or slightly yellowish oily and odourless liquids iatrogenic exposure to phthalates from blood only very slightly soluble in water. Phthalates are bags, injection syringes, intravenous canyllas much more readily soluble in organic solvents, and catheters, and from plastic parts of dialysers and the longer their side chain, the higher their is also a possibility (VELÍŠEK 1999; ČERNÁ 2000; liposolubility and the boiling point. Phthalates LOVEKAMP-SWAN & DAVIS 2003).
  • The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    >+'è ,'i5 1. The Disposition of Morphine and its 3- and 6- Glucuronide Metabolites in Humans and Sheep A Thesis submitted in Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Science at the University of Adelaide Robert W. Milne B.Pharm.(Hons), M.Sc. Department of Clinical and Experimental Pharmacology University of Adelaide August 1994 Ar,-,..u i.'..t itttlí I Corrigenda Page 4 The paragraph at the top of the page should be relocated to inimediatèly follow the section heading "1.2 Chemistry" on page 3" Page 42 (lines 2,5 and/) "a1-acid glycoProtein" should read "cr1-acid glycoprotein". Page 90 In the footnote "Amoxicillin" and "Haemacell" should read "Amoxycillin" and "Haemaccel", respectively. Page I 13 (tine -l l) "supernate!' should read "supernatant". ' '(j- Page I 15 (line -9) "supernate" should read "supernatalït1-. Page 135 To the unfinished sentence at the bottom of the page should be added "appears to be responsible for the formation of M3G, but its relative importance remains unknown. It was also proposed that morphine is involved in an enterohepatic cycle." Page 144 Add "Both infusions ceased at 6 hr" to the legend to Figure 6.3. Page 195 (line 2) "was" should fead "were". Page 198 (line l3) "ro re-€xamine" should read "to te-examine". Pages 245 to29l Bibliosraohv: "8r.." should read "Br.". For the reference by Bhargava et aI. (1991), "J. Pharmacol.Exp.Ther." should read "J. Pharmacol. Exp. Ther." For the reference by Chapman et aI. (1984), a full-stop should appear after"Biomed" . For the reference by Murphey et aI.
  • Commission Implementing Regulation (EU)

    Commission Implementing Regulation (EU)

    21.3.2013 EN Official Journal of the European Union L 80/1 II (Non-legislative acts) REGULATIONS COMMISSION IMPLEMENTING REGULATION (EU) No 230/2013 of 14 March 2013 on the withdrawal from the market of certain feed additives belonging to the group of flavouring and appetising substances (Text with EEA relevance) THE EUROPEAN COMMISSION, submitted before that deadline for the only animal category for which those feed additives had been auth­ orised pursuant to Directive 70/524/EEC. Having regard to the Treaty on the Functioning of the European Union, (4) For transparency purposes, feed additives for which no applications for authorisation were submitted within the Having regard to Regulation (EC) No 1831/2003 of the period specified in Article 10(2) of Regulation (EC) No European Parliament and of the Council of 22 September 1831/2003 were listed in a separate part of the 2003 on additives for use in animal nutrition ( 1 ), and in Community Register of Feed Additives. particular Article 10(5) thereof, (5) Those feed additives should therefore be withdrawn from Whereas: the market as far as their use as flavouring and appetising substances is concerned, except for animal species and categories of animal species for which applications for (1) Regulation (EC) No 1831/2003 provides for the auth­ authorisation have been submitted. This measure does orisation of additives for use in animal nutrition and not interfere with the use of some of the abovemen­ for the grounds and procedures for granting such auth­ tioned additives according to other animal species or orisation. Article 10 of that Regulation provides for the categories of animal species or to other functional re-evaluation of additives authorised pursuant to Council groups for which they may be allowed.
  • Ranvet's Filybol

    Ranvet's Filybol

    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
  • Test Items for Licensing Examination Krok 1 PHARMACY

    Test Items for Licensing Examination Krok 1 PHARMACY

    MINISTRY OF PUBLIC HEALTH OF UKRAINE Department of human resources policy, education and science Testing Board Student ID Last name Variant ________________ Test items for licensing examination Krok 1 PHARMACY (російськомовний варіант) General Instruction Every one of these numbered questions or unfinished statements in this chapter corresponds to answers or statements endings. Choose the answer (finished statements) that fits best and fill in the circle with the corresponding Latin letter on the answer sheet. Authors of items: Abramov A.V., Aleksandrova K.V., Andronov D.Yu., Bilyk O.V., Blinder O.O., Bobyr V.V., Bobrovska O.A., Bohatyriova O.V., Bodnarchuk O.V., Boieva S.S., Bolokhovska T.O., Bondarenko Yu.I., Bratenko M.K., Buchko O.V., Cherneha H.V., Davydova N.V., Deriuhina L.I., Didenko N.O., Dmytriv A.M., Doroshkevych I.O., Dutka N.M., Dynnyk K.V., Filipova L.O., Havryliuk I.M., Herhel T.M., Hlushkova O.M., Hozhdzinsky S.M., Hrekova T.A., Hrechana O.V., Hruzevsky O.A., Hudyvok Ya.S., Hurmak I.S., Ivanets L.M., Ivanov Ye.I., Kartashova T.V., Kava T.V., Kazakova V.V., Kazmirchuk H.V., Kernychna I.Z., Khlus K.M., Khmelnykova L.I., Klebansky Ye.O., Klopotsky H.A., Klymniuk S.I., Kobylinska L.I., Koldunov V.V., Kolesnyk V.P., Kolesnikova T.O., Komlevoy O.M., Kononenko N.M., Kornijevsky Yu.Y., Kremenska L.V., Krushynska T.Yu., Kryzhanovska A.V., Kryshtal M.V., Kukurychkin Ye.R., Kuznietsova N.L., Kuzmina A.V., Lisnycha A.M., Lychko V.H., Makats Ye.F., Maly V.V., Matvijenko A.H., Menchuk K.M., Minarchenko V.M., Mikheiev A.O., Mishchenko
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Safety Evaluation of Certain Food Additives and Contaminants. WHO Food Additives Series, No

    Safety Evaluation of Certain Food Additives and Contaminants. WHO Food Additives Series, No

    WHO FOOD Safety evaluation of ADDITIVES certain food additives SERIES: 64 and contaminants Prepared by the Seventy-third meeting of the Joint FAO/ WHO Expert Committee on Food Additives (JECFA) World Health Organization, Geneva, 2011 WHO Library Cataloguing-in-Publication Data Safety evaluation of certain food additives and contaminants / prepared by the seventy-third meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). (WHO food additives series ; 64) 1.Food additives - toxicity. 2.Food contamination. 3.Flavoring agents - analysis. 4.Flavoring agents - toxicity. 5.Risk assessment. I.Joint FAO/WHO Expert Committee on Food Additives. Meeting (73rd : 2010: Geneva, Switzerland). II.World Health Organization. III.Series. ISBN 978 924 166064 8 (NLM classification: WA 712) ISSN 0300-0923 © World Health Organization 2011 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications—whether for sale or for non- commercial distribution—should be addressed to WHO Press at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
  • Meta-Analysis of Benzodiazepine Use in the Treatment of Insomnia

    Meta-Analysis of Benzodiazepine Use in the Treatment of Insomnia

    Meta-analysis of benzodiazepine use in the treatment of insomnia Review Anne M. Holbrook, Renée Crowther, Ann Lotter, Chiachen Cheng, Derek King Synthèse Abstract From the Centre for Evaluation of Medicines, Objective: To systematically review the benefits and risks associated with the use St. Joseph’s Hospital of benzodiazepines to treat insomnia in adults. and McMaster University, Data sources: MEDLINE and the Cochrane Controlled Trials Registry were Hamilton, Ont. searched for English-language articles published from 1966 to December 1998 that described randomized controlled trials of benzodiazepines for the treatment This article has been peer reviewed. of insomnia. Key words included “benzodiazepines” (exploded), “randomized controlled trial” and “insomnia.” Bibliographies of relevant articles were re- CMAJ 2000;162(2):225-33 viewed for additional studies and manufacturers of benzodiazepines were asked to submit additional randomized controlled trial reports not in the literature. ß An overview of the diagnosis and management of insomnia in clinical Study selection: Articles were considered for the meta-analysis if they were ran- practice appears on page 216. domized controlled trials involving patients with insomnia and compared a ben- zodiazepine with placebo or another active agent. Of the 89 trials originally identified, 45 met our criteria, representing a total of 2672 patients. January 25, 2000 Data extraction: Data were extracted regarding the participants, the setting, details Table of Contents of the intervention, the outcomes (including adverse effects) and the method- ologic quality of the studies. Data synthesis: The meta-analyses of sleep records indicated that, when compared with placebo, benzodiazepines decreased sleep latency by 4.2 minutes (non- significant; 95% confidence interval [CI] –0.7 to 9.2) and significantly increased total sleep duration by 61.8 minutes (95% CI 37.4 to 86.2).
  • WSAVA List of Essential Medicines for Cats and Dogs

    WSAVA List of Essential Medicines for Cats and Dogs

    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
  • Oral Magnesium Gly Magnesium Glycerophosphate Ceroph

    Oral Magnesium Gly Magnesium Glycerophosphate Ceroph

    pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection.
  • Effects of Brotizolam, a New Thieno-Triazolo-Diazepine Derivative, on the Central Nervous System

    Effects of Brotizolam, a New Thieno-Triazolo-Diazepine Derivative, on the Central Nervous System

    In the present study, its actions on the central nervous system were investigated. Effects of Brotizolam, a New Thieno-Triazolo-Diazepine Derivative, on the Central Nervous System Kenjiro KIMISHIMA, Kyoko TANABE, Yukako KINOSHITA, Kooji TOKUYOSHI, Daisuke HOURI and Tatsuo KOBAYASHI Department of Pharmacology, Tottori University School of Medicine, Yonago 683, Japan Accepted August 24, 1984 Abstract-The effects of brotizolam, a new thieno-triazolo-diazepine derivative, on the central nervous system were analyzed in mice, rats and rabbits. Diazepam, estazolam and triazolam were used as control drugs. Brotizolam inhibited spon taneous motor activities; performances in the rotarod test, staircase test, and maximal electroshock seizure test; and pentetrazol or bemegride-induced convulsion. Moreover, catalepsy inducing action and potentiating effect on sleep elicited by pentobarbital or ethanol were observed. Following intraperitoneal or oral admin istration of brotizolam to rabbits with chronically implanted electrodes , the electro encephalographic profile in spontaneous EEG was characterized by slow waves with high amplitudes in the neocortex. The arousal responses by stimulation of the midbrain reticular formation and posterior hypothalamus were slightly inhibited, but the recruiting responses induced by stimulation of the diffuse thalamic projecting system were not inhibited, and seizure discharges induced by stimulation of the dorsal hippocampus were inhibited markedly. When motor activities and pente trazol-induced convulsions were observed as indices of tolerance for brotizolam, tolerance was not developed by repeated administration of brotizolam up to 14 days. These results suggested that brotizolam, a new thieno-triazolo-diazepine derivative, is judged to be a safer and stronger sleep inducer than diazepam and estazolam . Since the pioneering paper by Randall et et al.
  • The Metabolism of Anabolic Agents in the Racing Greyhound

    The Metabolism of Anabolic Agents in the Racing Greyhound

    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................